Merging mouse transcriptome analyses with parkinson's disease linkage studies

DNA Research

Volumn 14, Issue 2, 2007, Pages 79-89

  Gherbassi, Daniel ^a   Bhatt, Lavinia ^a   Thuret, Sandrine ^a   Simon, Horst H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Candidate genes; Dopaminergic neurons; Neurodegenerative disease; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; COMPLEMENTARY DNA; DNA BINDING PROTEIN; MAPT PROTEIN, HUMAN; NURR1 NUCLEAR RECEPTOR; TAU PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AGED; ANIMAL; ARTICLE; CHROMOSOME MAP; COMPARATIVE STUDY; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GENETICS; GENOME; HUMAN; MOUSE; PARKINSON DISEASE; SPECIES DIFFERENCE;

AGED; ALPHA-SYNUCLEIN; ANIMALS; CHROMOSOME MAPPING; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; GENOME, HUMAN; HUMANS; LINKAGE (GENETICS); MICE; PARKINSON DISEASE; SPECIES SPECIFICITY; TAU PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 34548382220     PISSN: 13402838     EISSN: 17561663     Source Type: Journal    
DOI: 10.1093/dnares/dsm007     Document Type: Article

References (72)

1. Olanow, C. W. and Tatton, W. G. 1999, Etiology and pathogenesis of Parkinson's disease, Annu. Rev. Neurosci., 22, 123-144.
2. Spillantini, M. G., Schmidt, M. L., Lee, V. M., et al. 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839-840.
3. Nussbaum, R. L. and Polymeropoulos, M. H. 1997, Genetics of Parkinson's disease, Hum. Mol. Genet., 6, 1687-1691.
4. Gasser, T. 2001, Genetics of Parkinson's disease, J. Neurol., 248, 833-840.
5. Polymeropoulos, M. H., Lavedan, C., Leroy, E., et al. 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045-2047.
6. Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., et al. 1997, Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27, Am. J. Hum. Genet., 60, 588-596.
7. Tassin, J., Durr, A., de Broucker, T., et al. 1998, Chromosome 6-linked autosomal recessive early-onset Parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum, and evidence of a small homozygous deletion in one family. The French Parkinson's Disease Genetics Study Group, and the European Consortium on Genetic Susceptibility in Parkinson's Disease, Am. J. Hum. Genet., 63, 88-94.
8. Jones, A. C., Yamamura, Y., Almasy, L., et al. 1998, Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region, Am. J. Hum. Genet., 63, 80-87.
9. Saito, M., Matsumine, H., Tanaka, H., et al. 1998, Refinement of the gene locus for autosomal recessive juvenile parkinsonism (AR-JP) on chromosome 6q25.2-27 and identification of markers exhibiting linkage disequilibrium, J. Hum. Genet., 43, 22-31.
10. Gasser, T., Muller-Myhsok, B., Wszolek, Z. K., et al. 1998, A susceptibility locus for Parkinson's disease maps to chromosome 2p13, Nat. Genet., 18, 262-265.
11. Waters, C. H. and Miller, C. A. 1994, Autosomal dominant Lewy body parkinsonism in a four-generation family, Ann. Neurol., 35, 59-64.
12. Singleton, A. B., Farrer, M., Johnson, J., et al. 2003, alpha-Synuclein locus triplication causes Parkinson's disease, Science, 302, 841.
13. Leroy, E., Boyer, R., Auburger, G., et al. 1998, The ubiquitin pathway in Parkinson's disease, Nature, 395, 451-452.
14. Valente, E. M., Bentivoglio, A. R., Dixon, P. H., et al. 2001, Localization of a novel locus for autosomal recessive earlyonset parkinsonism, PARK6, on human chromosome 1p35-p36, Am. J. Hum. Genet., 68, 895-900.
15. Valente, E. M., Brancati, F., Ferraris, A., et al. 2002, PARK6-linked parkinsonism occurs in several European families, Ann. Neurol., 51, 14-18.
16. van Duijn, C. M., Dekker, M. C., Bonifati, V., et al. 2001, Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36, Am. J. Hum. Genet., 69, 629-634.
17. Bonifati, V., Breedveld, G. J., Squitieri, F., et al. 2002, Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent data set, Ann. Neurol., 51, 253-256.
18. Funayama, M., Hasegawa, K., Kowa, H., et al. 2002, A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1, Ann. Neurol., 51, 296-301.
19. Najim al-Din, A. S., Wriekat, A., Mubaidin, A., Dasouki, M. and Hiari, M. 1994, Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome, Acta Neurol. Scand., 89, 347-352.
20. Hampshire, D. J., Roberts, E., Crow, Y., et al. 2001, Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36, J. Med. Genet., 38, 680-682.
21. Li, Y. J., Scott, W. K., Hedges, D. J., et al. 2002, Age at onset in two common neurodegenerative diseases is genetically controlled, Am. J. Hum. Genet., 70, 985-993.
22. Pankratz, N., Nichols, W. C., Uniacke, S. K., et al. 2003, Significant linkage of Parkinson disease to chromosome 2q36-37, Am. J. Hum. Genet., 72, 1053-1057.
23. Pankratz, N., Nichols, W. C., Uniacke, S. K., et al. 2002, Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations, Am. J. Hum. Genet., 71, 124-135.
24. Pankratz, N., Nichols, W. C., Uniacke, S. K., et al. 2003, Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families, Hum. Mol. Genet., 12, 2599-2608.
25. Strauss, K. M., Martins, L. M., Plun-Favreau, H., et al. 2005, Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease, Hum. Mol. Genet., 14, 2099-2111.
26. Scott, W. K., Nance, M. A., Watts, R. L., et al. 2001, Complete genomic screen in Parkinson disease/evidence for multiple genes, JAMA, 286, 2239-2244.
27. Bertoli-Avella, A. M., Giroud-Benitez, J. L., Bonifati, V., et al. 2003, Suggestive linkage to chromosome 19 in a large Cuban family with late-onset Parkinson's disease, Mov. Disord., 18, 1240-1249.
28. DeStefano, A. L., Golbe, L. I., Mark, M. H., et al. 2001, Genome-wide scan for Parkinson's disease/the Gene PD Study, Neurology, 57, 1124-1126.
29. Martinez, M., Brice, A., Vaughan, J. R., et al. 2004, Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease, J. Med. Genet., 41, 900-907.
30. Le, W. D., Xu, P., Jankovic, J., et al. 2003, Mutations in NR4A2 associated with familial Parkinson disease, Nat. Genet., 33, 85-89.
31. Kitada, T., Asakawa, S., Hattori, N., et al. 1998, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392, 605-608.
32. Wintermeyer, P., Kruger, R., Kuhn, W., et al. 2000, Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients, Neuroreport, 11, 2079-2082.
33. Harhangi, B. S., Farrer, M. J., Lincoln, S., et al. 1999, The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease, Neurosci. Lett., 270, 1-4.
34. Marx, F. P., Holzmann, C., Strauss, K. M., et al. 2003, Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease, Hum. Mol. Genet., 12, 1223-1231.
35. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., et al. 2004, Hereditary early-onset Parkinson's disease caused by mutations in PINK1, Science, 304, 1158-1160.
36. Martin, E. R., Scott, W. K., Nance, M. A., et al. 2001, Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease, JAMA, 286, 2245-2250.
37. Di Fonzo, A., Rohe, C. F., Ferreira, J., et al. 2005, A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease, Lancet, 365, 412-415.
38. Zhang, J., Song, Y., Chen, H. and Fan, D. 2005, The tau gene haplotype h1 confers a susceptibility to Parkinson's disease, Eur. Neurol., 53, 15-21.
39. Zheng, K., Heydari, B. and Simon, D. K. 2003, A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease, Arch. Neurol., 60, 722-725.
40. Xu, P. Y., Liang, R., Jankovic, J., et al. 2002, Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease, Neurology, 58, 881-884.
41. Kahle, P. J., Haass, C., Kretzschmar, H. A. and Neumann, M. 2002, Structure/function of alpha-synuclein in health and disease/rational development of animal models for Parkinson's and related diseases, J. Neurochem., 82, 449-457.
42. Giasson, B. I. and Lee, V. M. 2001, Parkin and the molecular pathways of Parkinson's disease, Neuron, 31, 885-888.
43. Shendelman, S., Jonason, A., Martinat, C., Leete, T. and Abeliovich, A. 2004, DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation, PLoS Biol., 2, e362.
44. von Bohlen Und Halbach, O. 2004, Synucleins and their relationship to Parkinson's disease, Cell Tissue Res., 318, 163-174.
45. Zetterstrom, R. H., Williams, R., Perlmann, T. and Olson, L. 1996, Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system, Brain Res. Mol. Brain Res., 41, 111-120.
46. Solano, S. M., Miller, D. W., Augood, S. J., Young, A. B. and Penney, J. B. Jr. 2000, Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain/genes associated with familial Parkinson's disease, Ann. Neurol., 47, 201-210.
47. Abeliovich, A., Schmitz, Y., Farinas, I., et al. 2000, Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system, Neuron, 25, 239-252.
48. Murray, I. J., Medford, M. A., Guan, H. P., et al. 2003, Synphilin in normal human brains and in synucleinopa-thies/studies with new antibodies, Acta Neuropathol. (Berl), 105, 177-184.
49. Xie, T., Tong, L., Barrett, T., et al. 2002, Changes in gene expression linked to methamphetamine-induced dopamin-ergic neurotoxicity, J. Neurosci., 22, 274-283.
50. Unoki, M. and Nakamura, Y. 2001, Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway, Oncogene, 20, 4457-4465.
51. Hauser, M. A., Li, Y. J., Takeuchi, S., et al. 2003, Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage, Hum. Mol. Genet., 12, 671-677.
52. Barrett, T., Xie, T., Piao, Y., et al. 2001, A murine dopamine neuron-specific cDNA library and microarray/increased COX1 expression during methamphetamine neurotoxicity, Neurobiol. Dis., 8, 822-833.
53. Stewart, G. J., Savioz, A. and Davies, R. W. 1997, Sequence analysis of 497 mouse brain ESTs expressed in the substantia nigra, Genomics, 39, 147-153.
54. Thuret, S., Bhatt, L., O'Leary, D. D. and Simon, H. H. 2004, Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta, Mol. Cell. Neurosci., 25, 394-405.
55. Hicks, A. A., Petursson, H., Jonsson, T., et al. 2002, A susceptibility gene for late-onset idiopathic Parkinson's disease, Ann. Neurol., 52, 549-555.
56. DeStefano, A. L., Lew, M. F., Golbe, L. I., et al. 2002, PARK3 influences age at onset in Parkinson disease/a genome scan in the GenePD study, Am. J. Hum. Genet., 70, 1089-1095.
57. Davies, R. W., Roberts, A. B., Morris, A. J., et al. 1994, Enhanced access to rare brain cDNAs by prescreening libraries/207 new mouse brain ESTs, Genomics, 24, 456-463.
58. Savioz, A. and Davies, R. W. 1995, Discovering genes with localised expression in the mouse brain/cDNAs specific to the substantia nigra, Gene, 154, 225-230.
59. Alberi, L., Sgado, P. and Simon, H. H. 2004, Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons, Development, 131, 3229-3236.
60. Simon, H. H., Saueressig, H., Wurst, W., Goulding, M. D. and O'Leary, D. D. 2001, Fate of midbrain dopaminergic neurons controlled by the engrailed genes, J. Neurosci., 21, 3126-3134.
61. Venter, J. C., Adams, M. D., Myers, E. W., et al. 2001, The sequence of the human genome, Science, 291, 1304-51.
62. Gregory, S. G., Sekhon, M., Schein, J., et al. 2002, A physical map of the mouse genome, Nature, 418, 743-750.
63. West, A. B., Zimprich, A., Lockhart, P. J., et al. 2001, Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes, Eur. J. Hum. Genet., 9, 659-666.
64. West, A., Farrer, M., Petrucelli, L., et al. 2001, Identification and characterization of the human parkin gene promoter, J. Neurochem., 78, 1146-1152.
65. Holzmann, C., Kruger, R., Saecker, A. M., et al. 2003, Polymorphisms of the alpha-synuclein promoter/expression analyses and association studies in Parkinson's disease, J. Neural. Transm., 110, 67-76.
66. Farrer, M., Maraganore, D. M., Lockhart, P., et al. 2001, alpha-Synuclein gene haplotypes are associated with Parkinson's disease, Hum. Mol. Genet., 10, 1847-1851.
67. Stamatoyannopoulos, J. A. 2004, The genomics of gene expression, Genomics, 84, 449-457.
68. Reveron, M. E., Savelieva, K. V., Tillerson, J. L., et al. 2002, L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice, Neurotoxicology, 23, 611-619.
69. Takahashi, N., Miner, L. L., Sora, I., et al. 1997, VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity, Proc. Natl Acad. Sci. USA, 94, 9938-9943.
70. Beal, M. F. 2003, Mitochondria, oxidative damage, and inflammation in Parkinson's disease, Ann. NY Acad. Sci., 991, 120-131.
71. Greenamyre, J. T. and Hastings, T. G. 2004, Biomedicine: Parkinson's - divergent causes, convergent mechanisms, Science, 304, 1120-1122.
72. Pruitt, K. D., Tatusova, T. and Maglott, D. R. 2003, NCBI Reference Sequence project: update and current status, Nucleic Acids Res., 31, 34-37.